Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

Imatinib mesylate (IM, Gleevec) has largely supplanted allogeneic hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML). Nevertheless, many people with CML eventually undergo HCT, raising the question of whether prior IM therapy impacts HCT success. Data f...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Lee, Stephanie J., Kukreja, Manisha, Wang, Tao, Giralt, Sergio A., Szer, Jeffrey, Arora, Mukta, Woolfrey, Ann E., Cervantes, Francisco, Champlin, Richard E., Gale, Robert Peter, Halter, Joerg, Keating, Armand, Marks, David I., McCarthy, Philip L., Olavarria, Eduardo, Stadtmauer, Edward A., Abecasis, Manuel, Gupta, Vikas, Khoury, H. Jean, George, Biju, Hale, Gregory A., Liesveld, Jane L., Rizzieri, David A., Antin, Joseph H., Bolwell, Brian J., Carabasi, Matthew H., Copelan, Edward, Ilhan, Osman, Litzow, Mark R., Schouten, Harold C., Zander, Axel R., Horowitz, Mary M., Maziarz, Richard T.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2008
Gaiak:
Transplantation
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2954751/
https://ncbi.nlm.nih.gov/pubmed/18664621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-02-141689
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak